CFDA sets out punishments for counterfeit clinical trial data

Chinese authorities try to go against this trend by enforcing new legislations of punishment and fines

The China Food and Drug Administration (CFDA) has released a notification setting out "Punishments in Relation to Problematic Clinical Trial Data During Inspections”. The notice is described as following in the wake of the State Council-ordered reforms to the drug and medical device review and approval system, and the self-audit campaign initiated by the CFDA from July 2015. The latest notice is open for public feedback on punishments.

Read the pdf
Copyright Widler & Schiemann AG 2015. All Rights Reserved. /